News
NVS
160.06
+1.18%
1.86
J.P. Morgan Sticks to Its Buy Rating for Novartis AG (NOVN)
TipRanks · 6h ago
ESIH, XSDR, HLTH: These ETFs Provide Exposure to Europe’s Top Healthcare Companies
TipRanks · 16h ago
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
Seeking Alpha · 23h ago
Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030
TipRanks · 1d ago
Novartis’ treatment of progressive supranuclear palsy granted orphan designation
TipRanks · 1d ago
Global Markets Crushed US Stocks In 2025 — ETFs Investors Are Watching Now
Benzinga · 1d ago
Correction to Super Bowl Ads Article on Feb. 6 and Feb. 7
The Wall Street Journal · 1d ago
AVDE: Diversified And Effective Active ETF At A Low Cost
Seeking Alpha · 1d ago
Oakmark International Strategy adds Unilever, Sanofi in Q4, exits Novartis
Seeking Alpha · 1d ago
International ETFs to Watch as Foreign Stock Markets Beat the US
NASDAQ · 2d ago
Novartis downgraded to Hold from Buy at DZ Bank
TipRanks · 2d ago
DZ BANK AG downgrades Novartis AG (NOVN) to a Hold
TipRanks · 3d ago
Weekly Report: what happened at NVS last week (0202-0206)?
Weekly Report · 3d ago
VIG vs. VYM vs. VYMI: Which Is Vanguard’s Best Dividend ETF for Reliable Passive Income?
TipRanks · 3d ago
Oakmark International Strategy Q4 2025 New Investments And Divestments
Seeking Alpha · 3d ago
Novartis breaks ground on new R&D center in San Diego
Seeking Alpha · 5d ago
Novartis baut neues globales Forschungszentrum in San Diego
Reuters · 5d ago
Novartis Breaks Ground on $23 Billion Biomedical Research Center in San Diego
Reuters · 5d ago
Novartis startet Bau eines globalen Biomedical Research Centers in San Diego
Reuters · 5d ago
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
TipRanks · 5d ago
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.